Getting a Second Opinion — on Your Genomic Report

Ask the laboratory directly for your raw sequencing files, usually provided in BAM or FASTQ format. Most accredited laboratories are obliged to supply this on request, though turnaround time varies. Your oncologist or the clinical coordinator at your treating centre can help you make the request formally if the laboratory is slow to respond. Having the raw data rather than just the PDF report gives a second laboratory far more to work with, and it avoids the need for a new tissue submission in most cases.

A variant of uncertain significance (VUS) is a change in the DNA sequence of your tumour that the laboratory has detected but cannot yet classify as clearly harmful or clearly harmless. It is not a diagnosis on its own, but it is not a finding to ignore either. VUS findings are common in comprehensive genomic profiling. Some are reclassified as actionable over time as more evidence accumulates, which is why a VUS result from more than a year ago is worth revisiting — and why seeking a second opinion specifically on VUS interpretation is one of the most productive uses of the process.

Yes, and in many situations this is the more thorough route. A molecular tumour board brings together oncologists, molecular pathologists, genetic counsellors, and sometimes clinical trial coordinators to review a complex genomic finding together. Some large hospitals convene these internally. CION can facilitate referral to a multidisciplinary review when a genomic report raises questions that a single specialist opinion may not fully resolve. Ask your oncologist whether your case qualifies for this level of review.

For most re-analysis requests, an accredited Indian laboratory with NABL or CAP certification is sufficient and considerably faster and less expensive than sending material abroad. International laboratories add value in specific situations: when a very rare variant requires access to a larger reference dataset, when you are considering enrolment in a trial run by an overseas centre, or when the international laboratory has particular expertise in your cancer type. Your oncologist can tell you whether your specific finding warrants the additional time and cost of an overseas submission.

Bring your original genomic report in full — not just the summary page. Bring any earlier reports if more than one test has been done. Bring a written list of the treatment recommendations you have received and note which oncologist gave each one. If a second opinion has already come back, bring that report too and mark the specific points where the two reports agree and disagree. The more specific your questions going in, the more useful the appointment will be for both you and your oncologist.

Coverage varies by insurer and by policy. Some policies cover genomic testing as part of cancer treatment but exclude repeat testing or second opinions explicitly. Before submitting a claim, ask your treating oncologist to document in writing why the second opinion is clinically necessary — for example, because the original result was ambiguous or because a major treatment decision depends on the finding. A formal referral letter is more likely to be accepted by an insurer than a self-initiated request. Check your policy document under the sections on diagnostic investigations and any cancer-specific riders.